Dual Antiplatelet Therapy After PCI According To Bleeding Risk: The HOST-BR Trial
The HOST-BR Trial demonstrated that in patients at high bleeding risk (HBR) as defined by ARC criteria, a 3-month course of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) reduced ischemic events without increasing bleeding risk compared to 1-month DAPT. In patients at low bleeding risk (LBR), 3-month DAPT was as effective as 12-month DAPT in preventing ischemic events, with a significantly lower risk of bleeding, according to a study presented by Dr. Hyo-Soo Kim, Seoul National University Hospital, Korea, in the Late-Breaking Clinical Trials session at ACC.25.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
